About Xenomimetics

The science behind what we do.

Xenomimetics Mission Statement

We are a university start up company founded to better understand human cancers and the cancer microenvironment and to advance the development of the Omental Tumor Xenograft (OTX) platform.

Xenomimetics current members of the Board of Managers are:

Richard Bankert
VMD PhD CEO and Co-Founder

Dr. Bankert Is a professor of microbiology and Immunology in the school of medicine and biomedical Sciences at the State University of New York, Buffalo (UB).  He is internationally recognized as an expert in the field of cancer immunology and is a leader in the area of the tumor microenvironment. His research has been continuously funded since 1989 with more than 10 million dollars of support from the National Institute of Health (NIH) . He serves on the editorial Boards of 3 publications:

Frontiers in Immunotherapies and Vaccines, Cancer Microenvironment, and the journal of Experimental and Clinical, Cancer Research.

He has served as a member of the Immunology Study Section of the NIH. He is a member of the American Association for the Advancement of Sciences, the American Association of Immunologists, and the New York Academy of Sciences. Dr. Bankert received his VMD from the School of Veterinary Medicine at University of Pennsylvania (UPenn) and his PhD from the Graduate School of Arts & Sciences, at Upenn.

Sathy Balu-lyer
PhD Co-Founder

Dr. Balu-lyer Is a professor of Pharmaceutical Sciences in the School of Pharmacy and Pharmaceutical Sciences at UB. He is a fellow of the American Association of Pharmaceutical Scientists (AAPS). His research encompasses areas of biophysics and bioengineering,  pharmacokinetics and pharmacodynamics, and immunology. Dr. Balu-lyer Received his PhD in molecular biophysics from the Indian Institute of Science in Bangalore, India, and was a postdoctoral fellow in the laboratory of Dr. Robert Straubinger in the Department of Pharmaceutical Sciences at the UB.

Robert Chau
PhD Managing Member and Co-Founder

D. Chau Received his PhD from the Horace  H. Rackham School of Graduate Studies At the University of Michigan in Ann Arbor. He has been with you be since 1988, with affiliations in the department of biology, the school of medicine, and the School of Pharmacy and pharmaceutical Sciences.

Advisory Board for Science and Medicine

Donald Mager

Dr. Mager is an associate professor in the department of pharmaceutical  science at UB.  he is currently president of the International Society of Pharmacometrics. He has served on the Clinical Pharmacology Advisory Committee to the FDA and the Editorial Advisory Boards of Biopharmaceutics and Drug Disposition and Journal of Pharmacokinetics and Pharmacodynamics. He was elected as a Fellow to the American College of Clinical Pharmacology, and has served as Chair of the Clinical Pharmacology and Translational Research section of AAPS, and  as a member of the Board of Directors to the American Society of Pharmacometrics. Dr. Mager is a graduate of UB, where he received both PharmD. And a PhD. He specializes in modeling and allometric scaling using Pharmacokinetic and Pharmacodynamics.

Kelvin Lee

Dr. Lee Is a professor and Chair of the Department of Immunology at the Roswell Park Cancer Institute in Buffalo, New York. His research interests are in the immunology and biology of multiple myeloma and normal plasma cells, dendritic cell biology, and novel therapeutics for hematological malignancies. Dr. Lee Is a graduate of the University of Michigan (UofM)  School of Medicine. He received his residency training in Internal Medicine at the University of Colorado, Denver, and did fellowship work in medical oncology at UofM.

Paul Wallace

Dr. Wallace is a professor of oncology and director of the Department of Flow and Image cytometry at the Roswell Park Cancer Institute, Buffalo. His research interests include the clinical diagnosis and monitoring of leukemia, myelodysplastic syndromes and lymphoma by flow cytometry, the application of flow cytometry to monitoring immune cell function, and immunotherapy of cancer with differentiated myeloid cells. Dr. Wallace received his PhD Department of microbiology &  Immunology at the Medical College of Pennsylvania, Philadelphia.

Xenomimetics LLC Has recruited other distinguished scientists and Physicians to be members of its Advisory Board for Science and Medicine. Their participation is pending approval from their parent institutions and companies.